Hikma Pharmaceuticals Beheer
Beheer criteriumcontroles 2/4
Hikma Pharmaceuticals' CEO is Riad Mishlawi, appointed in Sep 2023, has a tenure of 1.17 years. total yearly compensation is $1.55M, comprised of 21.5% salary and 78.5% bonuses, including company stock and options. directly owns 0.06% of the company’s shares, worth £2.50M. The average tenure of the management team and the board of directors is 1.2 years and 5.4 years respectively.
Belangrijke informatie
Riad Mishlawi
Algemeen directeur
US$1.6m
Totale compensatie
| Percentage CEO-salaris | 21.5% |
| Dienstverband CEO | 1.2yrs |
| Eigendom CEO | 0.06% |
| Management gemiddelde ambtstermijn | 1.2yrs |
| Gemiddelde ambtstermijn bestuur | 5.4yrs |
Recente managementupdates
Recent updates
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24
Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$285m |
| Mar 31 2024 | n/a | n/a | US$238m |
| Dec 31 2023 | US$2m | US$333k | US$190m |
Compensatie versus markt: Riad's total compensation ($USD1.55M) is below average for companies of similar size in the UK market ($USD3.40M).
Compensatie versus inkomsten: Insufficient data to compare Riad's compensation with company performance.
CEO
Riad Mishlawi (60 yo)
1.2yrs
Tenure
US$1,552,833
Compensatie
Mr. Riad Ali Mishlawi serves as Chief Executive Officer of Hikma Pharmaceuticals PLC since September 01, 2023 and serves as its Director since September 01, 2023. He had been the President of Injectables s...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman | 17.3yrs | US$3.57m | 0.38% £ 16.0m | |
| CEO & Director | 1.2yrs | US$1.55m | 0.060% £ 2.5m | |
| Executive Vice Chairman & President of MENA | 19.2yrs | US$2.84m | 0.63% £ 26.1m | |
| Chief Financial Officer | 13.8yrs | geen gegevens | 0.20% £ 8.4m | |
| Chief Information Officer | no data | geen gegevens | geen gegevens | |
| Associate Director of Investor Relations | no data | geen gegevens | geen gegevens | |
| General Counsel | no data | geen gegevens | geen gegevens | |
| Executive Vice President of Corporate Development and M&A | 10.7yrs | geen gegevens | 0.26% £ 10.7m | |
| Chief People Officer | 1.2yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Strategic Planning & Global Affairs | 6.8yrs | geen gegevens | geen gegevens | |
| President of Injectables Business | 1.2yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Corporate Quality Compliance/Health & Safety | less than a year | geen gegevens | geen gegevens |
1.2yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren management: HIK's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman | 17.3yrs | US$3.57m | 0.38% £ 16.0m | |
| CEO & Director | 1.2yrs | US$1.55m | 0.060% £ 2.5m | |
| Executive Vice Chairman & President of MENA | 19.2yrs | US$2.84m | 0.63% £ 26.1m | |
| Senior Independent Non-Executive Director | 2yrs | US$149.27k | geen gegevens | |
| Independent Non-Executive Director | 8.1yrs | US$176.38k | 0.0032% £ 132.9k | |
| Independent Non-Executive Director | 8.7yrs | US$159.69k | 0.0016% £ 65.6k | |
| Non-Executive Director | 19.1yrs | US$116.72k | 0.52% £ 21.8m | |
| Independent Non-Executive Director | 4.5yrs | US$149.85k | 0.0020% £ 84.3k | |
| Independent Non-Executive Director | 2yrs | US$127.05k | 0.00045% £ 18.7k | |
| Independent Non-Executive Director | 5.4yrs | US$134.68k | 0.00050% £ 20.8k | |
| Chairman of West-ward Pharmaceuticals | no data | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 2.1yrs | US$124.98k | geen gegevens |
5.4yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: HIK's board of directors are considered experienced (5.4 years average tenure).